Emergent BioSolutions Inc. (EBS: Quote) announced Friday that it has signed a license agreement with VaxInnate Corporation under which Emergent acquired the exclusive right to manufacture and sell VaxInnate's pandemic influenza vaccine candidate in the United States.
Emergent said VaxInnate will continue to develop its pandemic influenza vaccine candidate under its current BARDA contract and Emergent will manufacture the pandemic influenza vaccine candidate using flexible manufacturing technology.
Click here to receive FREE breaking news email alerts for Emergent BioSolutions Inc and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org